GlassScriptPhysician profile
George S Jerkovich
NPI 1578549200
$3,627.64
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $665 · 2020: $649 · 2021: $373 · 2022: $957 · 2023: $816 · 2024: $167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $983.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $983.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $495.38 | 2020-2023 | |
| Otsuka America Pharmaceutical, INC. | $425.70 | 2019-2024 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Abbvie INC. | $419.69 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $390.40 | 2019-2022 | |
| Alkermes, INC. | $313.40 | 2022-2024 | Aristada, Lybalvi, Aristada Initio |
| Lundbeck LLC | $301.39 | 2019-2024 | Rexulti, Brintellix |
| Sunovion Pharmaceuticals INC. | $296.95 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $241.06 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $171.40 | 2019-2023 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $150.72 | 2019-2024 | Uzedy, Austedo |
| Allergan, INC. | $81.39 | 2019-2020 | |
| Tris Pharma INC | $67.71 | 2020-2023 | Dyanavel Xr |
| Acadia Pharmaceuticals INC | $63.73 | 2020-2022 | |
| Corium, LLC | $56.01 | 2022-2023 | Azstarys |
| Ironshore Pharmaceuticals INC. | $31.31 | 2019-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $19.27 | 2024 | |
| Neos Therapeutics, LP | $17.94 | 2020 | |
| Vanda Pharmaceuticals INC. | $17.87 | 2019 | |
| Eisai INC. | $15.10 | 2020 | |
| Idorsia Pharmaceuticals US INC | $15.00 | 2023 | Quviviq |
| Adlon Therapeutics L.P. | $12.73 | 2020 | |
| Axsome Therapeutics, INC. | $12.47 | 2022 | |
| Sage Therapeutics, LLC | $11.02 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Jerkovich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.